In my recent post entitled “Step 7: How to optimize web meeting advisory boards“, I discussed the seventh step in augmenting the value, effectiveness and efficiency of customer advisory boards or working groups. We have already discussed mapping out your overall key opinion leader strategy and engagement plan, outlining the issues to be solved, the metrics…
In my recent post entitled “Step 6: How to optimize asynchronous online assignments“, I discussed the sixth step in augmenting the value, effectiveness and efficiency of customer advisory boards or working groups. We have already discussed mapping out your overall key opinion leader strategy and engagement plan, outlining the issues to be solved, the metrics for success,…
In my recent post entitled “Step 5: How to create a customer engagement plan“, I discussed the fifth step in our Value Creator Process which is used to develop a “Campaign of Interactions“, or “map”, of the strategic touchpoints you plan to expose your group of advisors to over a specific course of time. The modalities…
In my recent post entitled “Step 4: How to pick the best channels for customer touchpoints“, I discussed the fourth step in our Value Creator Process which helps you to develop a comprehensive, multi-touchpoint advisory board program with your key customers. It helps you consider the touchpoint modalities that you would ultimately like to employ in order to best engage…
Before a new product launches, many manufacturers need to decide if they are going to initiate a Special Access Program (SAP) (also referred to as an Early Access Program (EAP) in the US or a Compassionate Use Program (CUP) or Named Patient Program (NPP) in the EU) for their brand while they are going through regulatory approval. The…
As a medical, marketing or market access manager in today’s complex pharmaceutical environment, it has become increasingly difficult to bring innovation and value “beyond the pill” in conversations with key stakeholders. Discussions, controversies and healthcare needs have far exceeded the simple task of providing a medication with a slightly better efficacy and safety profile to other options…
Several key abstracts were presented at #ASCO17 covering data in lymphoma and chronic lymphocytic leukemia (see bottom of this post for the abstract details): Abstract 7500: First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: Results of the BRIGHT 5-year follow-up study. Abstract 7503: A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/antibody combinations…
The Canadian pharmaceutical market access environment can be quite complex at first blush. There are many agencies, organizations, and bodies to conform with along with a myriad of legislative bills and protocols to understand. This will be the first of many blogs that Impetus will create to help demystify this complex ecosystem in Canada. Our…
With the commencement of the American Society of Clinical Oncology (ASCO) Conference, the largest cancer focused conference in the world, we are reminded of the extraordinary number of innovations and achievements in research, in areas such as precision medicine and immunotherapy, that are helping to reshape the practice of cancer care today. Need for cancer clinical…
With over 38,000 attendees attending from all over the world, the American Society of Clinical Oncology (ASCO) Conference is the largest cancer focused conference in the world. For five consecutive days, stakeholders concerned about expanding cancer knowledge and improving cancer care for patients gather in Chicago to listen, speak, ask questions, interact at booths, read posters,…
